MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Gilead Sciences Inc.

Slēgts

SektorsVeselības aprūpe

106.04 -0.46

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

105.83

Max

107.54

Galvenie mērījumi

By Trading Economics

Ienākumi

530M

1.8B

Pārdošana

29M

7.6B

P/E

Sektora vidējais

274.553

57.333

EPS

1.9

Dividenžu ienesīgums

3.02

Peļņas marža

23.557

Darbinieki

17,600

EBITDA

-655M

3.1B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+9.79% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.02%

2.63%

Nākamais dividenžu datums

2025. g. 26. jūn.

Nākamais Ex dividenžu datums

2025. g. 13. jūn.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

8.7B

130B

Iepriekšējā atvēršanas cena

106.5

Iepriekšējā slēgšanas cena

106.04

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Gilead Sciences Inc. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. apr. 20:17 UTC

Peļņas

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

2025. g. 11. febr. 21:17 UTC

Peļņas

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

2025. g. 24. apr. 20:08 UTC

Peļņas

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences 1Q Rev $6.67B >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences 1Q Adj EPS $1.81 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences 1Q EPS $1.04 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences 1Q EPS $1.04 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences 1Q Net $1.32B >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences 1Q Adj EPS $1.81 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences 1Q Rev $6.7B >GILD

2025. g. 11. apr. 09:30 UTC

Top Ziņas

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

2025. g. 19. marts 14:50 UTC

Top Ziņas

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

2025. g. 28. febr. 12:00 UTC

Top Ziņas

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025. g. 11. febr. 22:13 UTC

Tirgus saruna
Peļņas

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

2025. g. 11. febr. 21:06 UTC

Peļņas

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

2025. g. 11. febr. 21:02 UTC

Peļņas

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

2025. g. 11. febr. 21:02 UTC

Peļņas

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

2025. g. 11. febr. 21:02 UTC

Peļņas

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

2025. g. 11. febr. 21:02 UTC

Peļņas

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

2025. g. 11. febr. 21:02 UTC

Peļņas

Gilead Sciences Raises Dividend 2.6%>GILD

2025. g. 11. febr. 21:02 UTC

Peļņas

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

Salīdzinājums

Cenas izmaiņa

Gilead Sciences Inc. Prognoze

Cenas mērķis

By TipRanks

9.79% augšup

Prognoze 12 mēnešiem

Vidējais 116.79 USD  9.79%

Augstākais 140 USD

Zemākais 89 USD

Pamatojoties uz 24 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Gilead Sciences Inc. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

24 ratings

18

Pirkt

6

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

105 / 106.5Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Very Strong Bearish Evidence

Ilgtermiņā

Weak Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.